Literature DB >> 34406841

Correlation of dynamic contrast-enhanced bone perfusion with morphologic ultra-short echo time MR imaging in medication-related osteonecrosis of the jaw.

Paul Schumann1,2, Sarah Morgenroth2,3, Florian A Huber2,3, Niels J Rupp2,4, Filippo Del Grande5, Roman Guggenberger2,3.   

Abstract

OBJECTIVES: To investigate whether dynamic contrast-enhanced (DCE)-MR bone perfusion could serve as surrogate for morphologic ultra-short echo time (UTE) bone images and to correlate perfusion with morphologic hallmarks in histologically proven foci of medication-related osteonecrosis of the jaw (MRONJ).
METHODS: Retrospective study including 20 patients with established diagnosis of MRONJ. Qualitative consensus assessment of predefined jaw regions by two radiologists was used as reference standard using Likert scale (0-3) for standard imaging hallmarks in MRONJ (osteolysis, sclerosis, periosteal thickening). DCE-MRI measurements performed in corresponding regions of the mandible were then correlated with qualitative scores. Regions were grouped into "non-affected" and "pathologic" based on binarized Likert scores of different imaging hallmarks (0-1 vs 2-3). DCE-MRI measurements among hallmarks were compared using Mann-Whitney-U-testing. ROC (receiver-operating-characteristic) analysis was performed for each of the perfusion parameters to assess diagnostic performance for identification of MRONJ using morphologic ratings as reference standard.
RESULTS: Median perfusion measurements of "pathologic" regions in wash-in, peak enhancement intensity and integrated area under the curve are significantly higher than those of "non-affected" regions, irrespective of reference imaging hallmark (p < 0.05). No significant perfusion differences were found between "pathologic" regions with and without osteolysis (p = 0.180). ROC analysis showed fair diagnostic performance of DCE-MRI parameters for identification of MRONJ (AUC 0.626-0.727).
CONCLUSIONS: DCE bone perfusion parameters are significantly increased in MRONJ compared to non-affected regions, irrespective of osteolysis. Due to certain overlap DCE-MRI bone perfusion cannot serve as full surrogate for UTE bone imaging but may enhance reader confidence.

Entities:  

Keywords:  Bisphosphonate-Associated Osteonecrosis of the Jaw; Drug-Related Side Effects and Adverse Reactions; Perfusion Weighted MRI

Mesh:

Substances:

Year:  2021        PMID: 34406841      PMCID: PMC8802699          DOI: 10.1259/dmfr.20210036

Source DB:  PubMed          Journal:  Dentomaxillofac Radiol        ISSN: 0250-832X            Impact factor:   2.419


  27 in total

1.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 2.  Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion.

Authors:  Yaron Gordon; Sasan Partovi; Matthias Müller-Eschner; Erick Amarteifio; Tobias Bäuerle; Marc-André Weber; Hans-Ulrich Kauczor; Fabian Rengier
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

3.  Increased perfusion in dynamic gadolinium-enhanced MRI correlates with areas of bone repair and of bone necrosis in patients with Kienböck's disease.

Authors:  Gunilla Müller; Sven Månsson; Markus F Müller; Martin Johansson; Anders Björkman
Journal:  J Magn Reson Imaging       Date:  2018-12-16       Impact factor: 4.813

4.  Is dynamic gadolinium enhancement needed in MR imaging for the preoperative assessment of scaphoidal viability in patients with scaphoid nonunion?

Authors:  Olivio F Donati; Marco Zanetti; Ladislav Nagy; Beata Bode; Andreas Schweizer; Christian W A Pfirrmann
Journal:  Radiology       Date:  2011-06-28       Impact factor: 11.105

5.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

Review 6.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

7.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

Review 8.  Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.

Authors:  Pongsapak Wongratwanich; Kiichi Shimabukuro; Masaru Konishi; Toshikazu Nagasaki; Masahiko Ohtsuka; Yoshikazu Suei; Takashi Nakamoto; Rinus G Verdonschot; Tomohiko Kanesaki; Pipop Sutthiprapaporn; Naoya Kakimoto
Journal:  Dentomaxillofac Radiol       Date:  2021-01-15       Impact factor: 3.525

9.  A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study.

Authors:  Zineb Assili; Gilles Dolivet; Julia Salleron; Claire Griffaton-Tallandier; Claire Egloff-Juras; Bérengère Phulpin
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

Review 10.  Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques.

Authors:  Geon-Ho Jahng; Ka-Loh Li; Leif Ostergaard; Fernando Calamante
Journal:  Korean J Radiol       Date:  2014-09-12       Impact factor: 3.500

View more
  2 in total

1.  Impact of acceleration on bone depiction quality by ultrashort echo time magnetic resonance bone imaging sequences in medication-related osteonecrosis of the jaw.

Authors:  Jonas M Getzmann; Florian A Huber; Dominik Nakhostin; Eva Deininger-Czermak; Paul Schumann; Tim Finkenstaedt; Filippo Del Grande; Roman Guggenberger
Journal:  Eur J Radiol Open       Date:  2022-04-23

Review 2.  [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].

Authors:  Matthias Tröltzsch; Markus Tröltzsch; Christoph Pautke; Sven Otto
Journal:  HNO       Date:  2022-01-20       Impact factor: 1.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.